Gesynta Pharma’s most advanced drug candidate, vipoglanstat, is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life and current drug treatments are inadequate for many patients.
Gesynta Pharma aims to exploit the anti-inflammatory and pain-relieving effects of mPGES-1 inhibition by developing products which provide distinct benefits compared to current therapy in areas of unmet medical need.
